Sirius Therapeutics
Sirius Therapeutics is an innovative biotech company developing novel RNAi therapies for global markets, focusing on cardiovascular diseases and chronic conditions. Founded in 2021, it has established research centers in the US and China, and aims to be a leading developer of RNAi therapeutics to transform disease management.
Industries
Nr. of Employees
small (1-50)
Sirius Therapeutics
11760 Sorrento Valley Road, Suite K, L, M, San Diego, California 92121, USA
Patents
Products
Clinical-stage siRNA therapeutic targeting coagulation factor XI (anti-FXI siRNA)
A hepatocyte-targeted siRNA program designed to reduce expression of coagulation factor XI for prevention or treatment of thromboembolic diseases; demonstrated durable target knockdown and clinical pharmacodynamic effects in Phase I studies.
Clinical-stage siRNA therapeutic targeting PCSK9 (anti-PCSK9 siRNA)
A hepatocyte-targeted siRNA program designed to inhibit PCSK9 mRNA to lower LDL cholesterol; completed Phase I enrollment with reported tolerability.
Multi-target siRNA pipeline (preclinical and discovery-stage candidates)
Portfolio of additional siRNA discovery-stage programs against multiple cardiovascular/metabolic targets with ongoing preclinical development.
Clinical-stage siRNA therapeutic targeting coagulation factor XI (anti-FXI siRNA)
A hepatocyte-targeted siRNA program designed to reduce expression of coagulation factor XI for prevention or treatment of thromboembolic diseases; demonstrated durable target knockdown and clinical pharmacodynamic effects in Phase I studies.
Clinical-stage siRNA therapeutic targeting PCSK9 (anti-PCSK9 siRNA)
A hepatocyte-targeted siRNA program designed to inhibit PCSK9 mRNA to lower LDL cholesterol; completed Phase I enrollment with reported tolerability.
Multi-target siRNA pipeline (preclinical and discovery-stage candidates)
Portfolio of additional siRNA discovery-stage programs against multiple cardiovascular/metabolic targets with ongoing preclinical development.
Expertise Areas
- RNAi/siRNA drug discovery
- Oligonucleotide chemistry and optimization
- Hepatocyte-targeted delivery for oligonucleotides
- Preclinical pharmacology and safety assessment
Key Technologies
- RNA interference (RNAi) therapeutics
- siRNA sequence design and in vitro screening
- Oligonucleotide chemical modification
- GalNAc-mediated hepatocyte targeting
News & Updates
Sirius Therapeutics Raised Nearly US$100 Million to Accelerate Clinical Development of siRNA Therapeutics
In October 2023, Sirius announced nearly $100 million raised through Series B financing to advance clinical development and innovation in RNAi therapies.
Sirius Therapeutics Appoints Dr. Qunsheng Ji as CEO and Board Member
In August 2022, Sirius appointed Dr. Ji as CEO, a leader with over 30 years of experience in drug development.
Sirius Completes First-in-Human Trial of FXI siRNA Anticoagulant in Australia
In February 2024, Sirius completed the first human trial of SRSD107 in Australia, showing promising safety and efficacy data.
Sirius Announces Positive Data from Phase 1 of FXI siRNA Anticoagulant
In December 2024, Sirius presented positive Phase 1 data at the American Society of Hematology Annual Meeting.
Sirius Appoints Dr. Qunsheng Ji as CEO and Board Member
In August 2022, Sirius announced the appointment of Dr. Ji as CEO.
Sirius Therapeutics Raised Nearly US$100 Million to Accelerate Clinical Development of siRNA Therapeutics
In October 2023, Sirius announced nearly $100 million raised through Series B financing to advance clinical development and innovation in RNAi therapies.
Sirius Therapeutics Appoints Dr. Qunsheng Ji as CEO and Board Member
In August 2022, Sirius appointed Dr. Ji as CEO, a leader with over 30 years of experience in drug development.
Sirius Completes First-in-Human Trial of FXI siRNA Anticoagulant in Australia
In February 2024, Sirius completed the first human trial of SRSD107 in Australia, showing promising safety and efficacy data.
Sirius Announces Positive Data from Phase 1 of FXI siRNA Anticoagulant
In December 2024, Sirius presented positive Phase 1 data at the American Society of Hematology Annual Meeting.
Sirius Appoints Dr. Qunsheng Ji as CEO and Board Member
In August 2022, Sirius announced the appointment of Dr. Ji as CEO.